- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy | ||
| Fr | BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts | ||
| Fr | BioMarin axes $270M rare disease asset after missing phase 3 endpoint | ||
| Fr | Novo Nordisk's CFO on the oral Wegovy rollout and beyond | ||
| Do | Double shot of Vistagen's anxiety nasal spray can't beat placebo in ph. 2 trial | ||
| Do | Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug | ||
| Do | BioVie's stock sinks 50% as company uses composite endpoint to make case for Parkinson's program | ||
| Do | Braveheart Bio charges past expectations with $382.5M IPO to fund cardio drug from Hengrui | ||
| Do | Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday | ||
| Do | Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027 | ||
| Mi | Sanofi suspends chronic lung disease phase 2 study, tied to 'strategic business reasons' | ||
| Mi | Lilly drops another gene therapy trial from $1B Prevail buyout | ||
| Mi | Novo CEO accepts 'couple of setbacks' in R&D as CagriSema posts more mixed data | ||
| Mi | Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO | ||
| Di | Amgen drops early-stage obesity drug, upping pressure on MariTide | ||
| Di | Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart | ||
| Di | Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout | ||
| Di | Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex's Journavx | ||
| Di | Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact | ||
| Di | Merck's $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials | ||
| Mo | BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger | ||
| 31.07. | Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail | ||
| 31.07. | Apnimed's IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch | ||
| 30.07. | BMS CEO Boerner doesn't 'feel any compulsion to make deals' despite lack of M&A this year | ||
| 30.07. | Attovia, Braveheart Bio and Vogenx seek more than $500M across trio of IPOs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.